NDA 211994 · Viiv Hlthcare
Dovato
Dolutegravir Sodium, Lamivudine · Oral · Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor; Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Priority reviewLast checked: Nov 20, 2026Latest source record: Oct 28, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Apr 8, 2019
Approved uses
9
Original approval plus efficacy supplements
Registered trials
306
91 Phase 3, 30 recruiting
FAERS reports
3,600
1,372 serious, 120 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: PATIENTS CO-INFECTED WITH HEPATITIS B VIRUS (HBV) AND HUMAN IMMUNODEFICIENCY VIRUS (HIV-1): EMERGENCE OF LAMIVUDINE-RESISTANT HBV AND EXACERBATIONS OF HBV All patients with HIV-1 should be tested for the presence of HBV prior to or when initiating DOVATO. Emergence of lamivudine-resistant HBV variants associated with lamivudine-containing antiretroviral regimens has been reported. If DOVATO is used in patients co-infected with HIV-1 and HBV, additional treatment should be considered for appropriate treatment of chronic HBV; otherwise, consider an alternative regimen. Severe acute exacerbations of HBV have been reported in patients who are co-infected with HIV-1 and HBV and have discontinued lamivudine, a component of DOVATO. Closely monitor hepatic function in these patients and, if appropriate, initiate anti-HBV treatment [see Warnings and Precautions ( 5.1 )] . WARNING:...
What it is approved for
From the label in effect Oct 29, 2025.
DOVATO is indicated as a complete regimen for the treatment of HIV-1 infection in adults and adolescents 12 years of age and older and weighing at least 25 kg with no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of DOVATO. DOVATO, a two-drug combination of dolutegravir (integrase strand transfer inhibitor [INSTI]) and lamivudine (nucleoside analogue reverse transcriptase inhibitor [NRTI]) is indicated as a complete regimen for the treatment of HIV-1 infection in adults and adolescents 12 years of age and older and weighing at least 25 kg with no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of DOVATO. ( 1 )
Mechanism: DOVATO is a fixed-dose combination of the HIV‑1 antiretroviral agents, dolutegravir and lamivudine [see Microbiology ( 12.4 )] .
Therapeutic areas: Infectious disease and vaccines · Rare and genetic disease
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 5, 2024 Supplement 18 · Efficacy LetterLabel
- Apr 5, 2024 Supplement 19 · Efficacy LetterLabel
- Jan 25, 2023 Supplement 14 · Efficacy LetterLabel
- Jan 20, 2022 Supplement 13 · Efficacy LabelLetter
- Jan 20, 2022 Supplement 12 · Efficacy LabelLetter
- Mar 1, 2021 Supplement 10 · Efficacy LetterLabel
- Aug 6, 2020 Supplement 7 · Efficacy LetterLabel
- Aug 6, 2020 Supplement 6 · Efficacy LetterLabel
- Apr 8, 2019 Original approval · Type 4 - New Combination · priority review LabelLetterReview
1 products under this application
- DOVATO · DOLUTEGRAVIR SODIUM EQ 50MG BASE; LAMIVUDINE 300MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Dolutegravir" as an intervention, any sponsor and status, largest first.
- Long-Acting HIV Pre-Exposure Prophylaxis Integrated With Sexual and Reproductive Health - cRCTPivotal-lookingRecruiting
Africa Health Research InstituteAcademic, hospital or other
NCT06250504 · 2,052 participants (planned) · Start Feb 27, 2024 · Primary completion Apr 30, 2026
Drug: APRETUDE (cabotegravir) 600 mg\3 mL; DAPIRING (Dapivirine) 25mg Vaginal Ring and 2 more · For: HIV Infections
Sites: Somkele, South Africa
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT02140255 · 1,120 participants (planned) · Start Jan 23, 2015 · Primary completion Jan 31, 2028
Drug: Nucleoside Reverse Transcriptase Inhibitors (NRTIs); Nevirapine (NVP) and 5 more · For: HIV Infection
Sites: La Jolla, California; Los Angeles, California; Aurora, Colorado · 47 sites in all
- ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral TherapyPivotal-lookingCompleted
Professor Francois VenterAcademic, hospital or other
NCT03122262 · 1,110 participants · Start Jan 16, 2017 · Primary completion Apr 30, 2022
Drug: Dolutegravir; Tenofovir Alafenamide and 2 more · For: HIV-1 Infection
Sites: Johannesburg, South Africa · 4 sites in all
- POC HIV Testing and Early DTG Use for InfantsActive, not recruiting
Harvard School of Public Health (HSPH)Academic, hospital or other
NCT05393193 · 900 participants (planned) · Start Jul 4, 2022 · Primary completion Mar 16, 2026
Drug: DTG/ABC/3TC · For: HIV
Sites: Gaborone, Botswana
- Antiretroviral Therapy for Acute and Chronic HIV InfectionPivotal-lookingRecruiting
SEARCH Research FoundationAcademic, hospital or other
NCT00796263 · 900 participants (planned) · Start May 13, 2009 · Primary completion Jun 2033
Drug: HAART · For: Acute HIV Infection; Chronic HIV Infection
Sites: Bangkok, Thailand
- Optimizing Malaria Treatment for HIV-Malaria Co-infected IndividualsPivotal-lookingStatus unknown
Makerere UniversityAcademic, hospital or other
NCT04708496 · 888 participants (planned) · Start Jan 18, 2021 · Primary completion Jan 2024
Drug: Artemether-lumefantrine · For: HIV Coinfection; Malaria
Sites: Kampala, Uganda; Tororo, Uganda
- Shortened Regimen for Drug-susceptible TB in ChildrenPivotal-lookingRecruiting
Johns Hopkins UniversityAcademic, hospital or other
NCT06253715 · 860 participants (planned) · Start Jan 15, 2025 · Primary completion Sep 30, 2027
Drug: Isoniazid; Rifampin and 4 more · For: Tuberculosis; Tuberculosis, Pulmonary; Tuberculosis, Lymph Node and 1 more
Sites: Chennai, India; Pune, India; Bandung, Indonesia · 9 sites in all
- A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)Pivotal-lookingCompleted
ViiV HealthcareGSK (GSK)
NCT01263015 · 844 participants · Start Feb 1, 2011 · Primary completion May 14, 2012
Drug: Dolutegravir; Atripla and 4 more · For: Infection, Human Immunodeficiency Virus I
Sites: Hobson City, Alabama; Little Rock, Arkansas; Bakersfield, California · 145 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- product dose omission issue1,096
- inappropriate schedule of product administration256
- product dose omission in error224
- product use issue195
- anxiety155
- pain142
- drug ineffective137
- rash126
- fatigue122
- viral load increased121
- pathogen resistance119
- off label use110
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 4 |
| 2018 | 5 |
| 2019 | 90 |
| 2020 | 214 |
| 2021 | 306 |
| 2022 | 546 |
| 2023 | 865 |
| 2024 | 761 |
| 2025 | 577 |
| 2026 | 228 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Dovato (Dolutegravir Sodium/Lamivudine)
2024 spending
$541M
Beneficiaries
19,337
176,933 claims
Per beneficiary
$27,981
$98.50 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $93,204,980 |
| 2021 | $187,788,540 |
| 2022 | $309,276,671 |
| 2023 | $433,449,386 |
| 2024 | $541,076,553 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and Safety of Dual Therapy With Dolutegravir/Lamivudine in Treatment-naive Persons With CD4 Counts <200/mm3: 48-Week Results of the DOLCE Study.
Figueroa MI, Brites C, Cecchini D, et al. · Clin Infect Dis 2026 · Randomized Controlled Trial, Multicenter Study
- Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial.
Ryan P, Blanco JL, Masia M, et al. · Lancet HIV 2025 · Multicenter Study, Randomized Controlled Trial
- Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection.
Cahn P, Sierra Madero J, Arribas JR, et al. · AIDS 2022 · Clinical Trial, Phase III, Multicenter Study
- Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.
Orkin C, Arasteh K, Górgolas Hernández-Mora M, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Equivalence Trial
- Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.
Orkin C, DeJesus E, Sax PE, et al. · Lancet HIV 2020 · Clinical Trial, Phase III, Comparative Study
- Virologic failure and HIV drug resistance on simplified, dolutegravir-based maintenance therapy: Systematic review and meta-analysis.
Wandeler G, Buzzi M, Anderegg N, et al. · F1000Res 2018 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: GSK
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.